Nova Southeastern University researchers have begun a clinical trial testing AstraZeneca's monoclonal antibody sipavibart as a potential treatment for Long COVID, funded by the Schmidt Initiative for Long COVID.
INOVIO's Phase 1 trial demonstrates DNA-encoded monoclonal antibodies (DMAbs) maintained stable levels for 72 weeks in all participants, potentially overcoming the short half-life limitations of traditional antibody therapies.
The European Medicines Agency's CHMP has issued a positive opinion recommending approval of Kavigale for preventing COVID-19 in immunocompromised patients who may not respond adequately to vaccination.
The CHMP recommended eight medicines for approval in November, including Augtyro for advanced solid tumors and Lazcluze for first-line treatment of advanced non-small cell lung cancer.